Search Results 261-270 of 18824 for alzheimers
Murray previously led research that identified tau, rather than amyloid, as the protein driving cognitive decline in Alzheimer's disease. This work was ...
About this study. Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the ...
Ronald Petersen, director of the Alzheimer's Disease Research Center at Mayo Clinic, says aducanumab targets the amyloid plaques in the brain that are believed ...
Research. Researchers at Mayo Clinic study Alzheimer's disease, mild cognitive impairment, and other conditions that affect memory and thinking skills.
However, as Alzheimer's disease gets worse, there will be less and less ACh, so rivastigmine may not work as well. This medicine is available only with your ...
Verubecestat is a BACE inhibitor because it cuts a large protein called the Alzheimer precursor protein into pieces that include one fragment called beta- ...
That number is expected to triple by 2050 if effective treatments cannot be found. Alzheimer's has no cure and the five medications the U.S. Food and Drug ...
Watch Mayo Clinic neurologist Ronald C. Petersen, M.D., Ph.D., talk about mild cognitive impairment on HBO — The Alzheimer's Project. Research Profiles. Edit ...
Last week, the Food and Drug Administration approved aducanumab to treat Alzheimer's disease, which is a progressive brain disorder that is the most common ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make a gift before July 31 and it can be doubled in impact thanks to a $100,000 Summer Challenge.